Basic Information



GTO ID GTC3992
Trial ID NCT01582516
Disease Brain Glioma
Altered gene E1A|RGD
Therapeutic/Target gene Therapeutic gene
TherapyDNA oncolytic virus
Treatment Ad5-Delta 24RGD|DNX-2401|tasadenoturev
PhasePhase1|Phase2
Recruitment statusCompleted
TitleA Phase I/II Trial of a Conditionally Replication-competent Adenovirus (Delta-24-rgd) Administered by Convection Enhanced Delivery in Patients With Recurrent Glioblastoma
Year2010
CountryNetherlands
Company sponsorErasmus Medical Center
Other ID(s)NL24958.000.08
Vector information
Vectoradenovirus
ConstructAd5-Delta 24RGD
Vector typetumor-selective, replication-competent oncolytic adenovirus
Transgene/Inserted geneRGD-motif, which was engineered into the fiber H-loop, enabling the virus to use αvβ3 or αvβ5 integrins to enter cells.
Regulatory elementRGD-motif
Viral genome modification24-base-pair deletion in the E1A gene

Clinical Result

Cohort1: dose level 1
Administration route intratumoral infusion
Dosage 1E7 viral particles (vp)
Age Adult, Older_Adult
Cohort2: dose level 2
Administration route intratumoral infusion
Dosage 1E8 viral particles (vp)
Age Adult, Older_Adult
Cohort3: dose level 3
Administration route intratumoral infusion
Dosage 1E viral particles (vp)
Age Adult, Older_Adult
Cohort4: dose level 4
Administration route intratumoral infusion
Dosage 1E10 viral particles (vp)
Age Adult, Older_Adult
Cohort5: dose level 5
Administration route intratumoral infusion
Dosage 3E10 viral particles (vp)
Age Adult, Older_Adult
Cohort6: dose level 6
Administration route intratumoral infusion
Dosage 1E11 viral particles (vp)
Age Adult, Older_Adult

Relationship Graph

Overview of Knowledge Graph